29 stories mentioning BNTXUpdated 6d ago
Every FINWIRES story that references BNTX, newest first.
BioNTech (BNTX) has authorized a new $1 billion share repurchase program for its American depositary shares, the company said Thursday.The program will run until and including May 6, 2027, BioNTech said.Price: $94.10, Change: $-1.16, Percent Change: -1.22%
Health care stocks rose Tuesday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3% each.The iShares Biotechnology ETF (IBB) was shedding 0.4%.In corporate news, Pfizer's (PFE) Q1 results surpassed analysts' estimates as robust demand across its key brands offset weakening sales of its COVID-19 products. Its shares declined 0.7%.Merck (MRK) shares added 0.4% after the company said Tuesday it has completed the acquisition of Terns Pharmaceuticals after a cash tender offer at $53 per share. Terns' stock will no longer be listed on Nasdaq, it said.BioNTech (BNTX) shares dropped 3.5% after the company reported a wider adjusted loss and lower revenue in Q1.
(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts polled by FactSet expect 2.22 billion euros.BioNTech shares were down nearly 4.4% in Tuesday premarket activity.Price: $96.56, Change: $-2.79, Percent Change: -2.81%
(Corrects the year-ago revenue to 182.8 million euros in the third paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 million euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts expect 2.22 billion euros.The company said it plans to exit operations at manufacturing sites in Idar-Oberstein, Marburg and Singapore, as well as CureVac's sites, affecting up to about 1,860 positions. The moves are expected to be completed by 2027 and deliver about 500 million euros in annual cost savings by 2029.BioNTech shares were down 2.4% in Tuesday trading.Price: $96.80, Change: $-2.55, Percent Change: -2.57%
European equities traded in the US as American depositary receipts were higher late Tuesday morning, rising 0.27% to 1,794.86 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by brewing firm Anheuser-Busch InBev (BUD) and medical device maker EDAP TMS (EDAP), which advanced 9% and 3% respectively. They were followed by telecommunications companies Ericsson (ERIC) and Nokia (NOK), which rose 2.5% and 2.4% respectively.The decliners from continental Europe were led by semiconductor company Sequans Communications (SQNS) and internet advertising firm Criteo (CRTO), which shed 9.7% and 3.9% respectively. They were followed by biotech firm BioNTech (BNTX) and consumer goods company Unilever (UL), which fell 3.1% and 0.6% respectively.The gainers from the UK were led by Biodexa Pharmaceuticals (BDRX) and insurance company Prudential (PUK), which climbed 32% and 2.2% respectively. They were followed by education company Pearson (PSO) and mining company BHP Group (BHP) were up 1.8% and 1.5% respectively.The decliners from the UK and Ireland were led by lender HSBC (HSBC) and Mereo BioPharma (MREO), which fell 5% and 2.1% respectively. They were followed by Lloyds Banking Group (LYG) and software firm Endava (DAVA), which were down 1.9% each.
(Updates with layoff plan in the sixth paragraph and recent stock price move in the last paragraph.)BioNTech (BNTX) reported a Q1 adjusted loss Tuesday of 1.95 euros ($2.28) per diluted share, widening from a loss of 1.79 euros a year earlier.Analysts polled by FactSet expected a loss of 1.27 euros.Revenue for the quarter ended March 31 was 118.1 million euros, compared with 182.8 billion euros a year earlier.Analysts surveyed by FactSet expected 164.6 million euros.For 2026, the company reaffirmed revenue of between 2 billion euros and 2.30 billion euros. Analysts expect 2.22 billion euros.The company said it plans to exit operations at manufacturing sites in Idar-Oberstein, Marburg and Singapore, as well as CureVac's sites, affecting up to about 1,860 positions. The moves are expected to be completed by 2027 and deliver about 500 million euros in annual cost savings by 2029.BioNTech shares were down 2.4% in Tuesday trading.Price: $96.96, Change: $-2.39, Percent Change: -2.41%
European equities traded in the US as American depositary receipts were trending marginally higher late Friday morning, rising 0.05% to 1,824.45 on the S&P Europe Select ADR Index, which is up 1.25% for the week so far.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and pharmaceutical company Novo Nordisk (NVO), which climbed 6.3% and 3.6% respectively. They were followed by biopharmaceutical company Cellectis (CLLS) and consumer goods company Unilever (UL), which advanced 3.3% and 3% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and furniture maker Natuzzi (NTZ), which dropped 6% and 3.5% respectively. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which lost 3.3% and 2.4% respectively.The gainers from the UK were led by educational publisher Pearson (PSO) and biopharmaceutical company Akari Therapeutics (AKTX), which rose 3.2% and 2.8% respectively. They were followed by biopharmaceutical company Bicycle Therapeutics (BCYC) and cruise line operator Carnival (CUK), which were up 2.7% and 2.5% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Amarin (AMRN) and oil and gas company BP (BP), which fell 2.8% and 1.9% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and oil and gas company Shell (SHEL), which were down 1.4% and 1.2% respectively.
European equities traded in the US as American depositary receipts were trending lower late Monday morning, down 0.39% to 1,794.56 on the S&P Europe Select ADR Index.From continental Europe, the gainers were led by telecommunications company Nokia (NOK) and semiconductor company Sequans Communications (SQNS), which climbed 6.8% and 5.6% respectively. They were followed by 3D printer company Materialise (MTLS) and biopharmaceutical company DBV Technologies (DBVT), which advanced 3.5% and 3.4% respectively.The decliners from continental Europe were led by biotech firm BioNTech (BNTX) and internet browser company Opera (OPRA), which dropped 2.9% and 1.5% respectively. They were followed by oil and gas company Eni (E) and accommodations booking site trivago (TRVG), which lost 1% and 0.7% respectively.The gainers from the UK were led by medical device maker Smith & Nephew (SNN), which rose 1.4%. They were followed by biopharmaceutical company NuCana (NCNA) and biotech firm Autolus Therapeutics (AUTL), which were up 1.3% and 1% respectively.The decliners from the UK and Ireland were led by biopharmaceutical company Akari Therapeutics (AKTX) and cruise line operator Carnival (CUK), which fell 6% and 1.6% respectively. They were followed by oil and gas company Shell (SHEL) and hospitality company InterContinental Hotels Group (IHG), which were down 1.4% and 1.2% respectively.
Sierk Poetting, Chief Operating Officer, on April 22, 2026, sold 50,000 shares in Biontech (BNTX) for $5,527,960. Following the Form 4 filing with the SEC, Poetting has control over a total of 399,387 ordinary shares of the company, with 399,387 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1776985/000195558926000002/xslF345X05/wk-form4_1776974561.xml
Showing 21-29 of 29
